The project aims to develop and deliver potent and selective protein-protein inhibitors of BCL6 function. Chromosomal translocation of the BCL6 is known to cause deregulated expression of its target genes, which include tumour suppressors such as p53. The constitutive expression of BCL6 is thought to play a pivotal role in the development of Diffuse Large B-Cell Lymphoma and Follicular Lymphoma, both sub-types of Non-Hodgkin’s Lymphoma for which there is a need for new therapies. This presents a genetically defined patient population who would benefit from a selective BCL6 inhibitor.
The project is being carried out at the Institute of Cancer Research, ICR and is strongly enabled by a crystallography and structure based design.
CPF acquired worldwide rights to the project in July 2015 and it is available for partnering.